Is Human Growth Hormone Bad for Your Heart?

Growth hormone sits in a peculiar spot in cardiology: too little of it weakens the heart, while too much damages it. The answer to whether human growth hormone (HGH) harms your heart depends almost entirely on how much is circulating, for how long, and whether your body actually needs it. In people with a genuine deficiency, replacing growth hormone tends to improve heart structure and function. In people who already have normal levels and take it anyway, the hormone can push the heart toward the same kind of damage seen in acromegaly, a disease of chronic growth hormone excess. The dose makes the poison, and the margin between therapeutic and harmful is not wide.

How Growth Hormone Acts on the Heart

Growth hormone does not simply pass through the cardiovascular system on its way to bones and muscles. It acts directly on heart muscle cells, triggering them to grow larger and produce specific proteins involved in contraction. Much of this effect is mediated through insulin-like growth factor 1 (IGF-1), which the liver produces in response to growth hormone. Together, GH and IGF-1 stimulate the heart to maintain its wall thickness, contractile strength, and overall architecture.¹ In laboratory models, IGF-1 signaling through a pathway called PI3K promotes a form of heart growth that looks a lot like what happens with regular exercise: the heart gets bigger and stronger without developing scar tissue or stiffness.² Mice engineered to overexpress the IGF-1 receptor in their hearts developed larger hearts with better pumping ability and no signs of disease, even after more than a year.³

This is the key distinction that runs through the entire topic: there is healthy heart growth and unhealthy heart growth. The IGF-1/PI3K route produces the healthy kind. Problems begin when growth hormone levels stay chronically elevated beyond what that pathway can handle, activating other signaling routes that lead to fibrosis, stiffening, and eventual heart failure.

What Growth Hormone Deficiency Does to the Heart

People who produce too little growth hormone, whether from a pituitary problem in childhood or damage to the pituitary gland later in life, do not just miss out on height. Their hearts suffer measurably. Studies using echocardiography have found that adults with growth hormone deficiency tend to have thinner heart walls, reduced heart mass, lower pumping efficiency, and impaired ability to fill properly between beats.⁴ Their exercise capacity drops, and in severe cases, the heart can weaken to the point of dilated cardiomyopathy and outright heart failure.⁵

Beyond the heart muscle itself, growth hormone deficiency is associated with stiffer arteries and poorly functioning endothelium, the inner lining of blood vessels that helps regulate blood flow and prevents plaque formation. A randomized, placebo-controlled trial found that adults with growth hormone deficiency had measurably worse endothelial function and greater large-artery stiffness compared to healthy controls.⁶ This vascular dysfunction is an early step toward atherosclerosis, the buildup of fatty plaques in arteries that causes heart attacks and strokes. Inflammatory markers associated with cardiovascular risk, including C-reactive protein and fibrinogen, tend to run higher in GH-deficient patients.⁷

So the starting point is that the heart needs growth hormone. Without adequate levels, both the heart muscle and the blood vessels deteriorate in ways that raise cardiovascular risk.

What Chronic Growth Hormone Excess Does to the Heart

The opposite extreme is acromegaly, a condition in which a pituitary tumor churns out excessive growth hormone for years or decades. The cardiac consequences are well documented and serious. Chronic GH and IGF-1 excess leads to a specific pattern of damage called acromegalic cardiomyopathy: the walls of both ventricles thicken concentrically, the heart becomes stiff and fills poorly between beats, and over time the pumping ability degrades.⁸ On biopsy, the tissue shows progressive scarring (fibrosis) that replaces normal muscle with stiff connective tissue.⁴

Left untreated, acromegalic cardiomyopathy progresses from diastolic dysfunction (trouble relaxing) to systolic dysfunction (trouble squeezing), eventually ending in congestive heart failure. Heart failure from this cause has historically been one of the leading killers in acromegaly.⁹ Valve problems and abnormal heart rhythms also show up at higher rates in acromegaly patients, compounding the damage.¹⁰

The good news is that treating the underlying excess, through surgery, medication, or both, can partially reverse these changes, especially if caught before fibrosis becomes extensive. But the reversal is often incomplete, which is why cardiologists and endocrinologists emphasize that controlling growth hormone levels in acromegaly patients is urgent, not optional.

Molecular work in heart biopsies from acromegaly patients has shown that a tiny regulatory molecule called miR-1, which normally keeps IGF-1 signaling in check, gets suppressed as growth hormone and IGF-1 levels climb. The lower miR-1 drops, the thicker the heart walls become.¹¹ This helps explain why the transition from healthy adaptive growth to pathological thickening is not a clean switch but a gradient, one that depends on how long and how far growth hormone levels exceed the normal range.

GH Replacement in Deficient Patients

For people diagnosed with genuine growth hormone deficiency, replacement therapy consistently improves cardiac function. A meta-analysis pooling data from multiple trials found that GH treatment increased ejection fraction, thickened the heart walls toward normal, and improved how well the heart fills and empties.¹² The same analysis showed that diastolic blood pressure dropped modestly and markers of heart strain improved. A separate earlier meta-analysis published in Circulation reached a similar conclusion: GH replacement could improve both the structure and function of the heart in deficient adults.¹³

The vascular benefits are real, too. GH replacement reduced arterial stiffness and improved endothelial function in the randomized trial mentioned earlier, and it lowered C-reactive protein, a marker linked to atherosclerosis risk.⁶ These changes collectively point toward a lower probability of developing cardiovascular disease down the line.

That said, GH replacement does not erase every metabolic abnormality associated with deficiency. Some cardiometabolic risk factors persist even after hormone levels are normalized, suggesting that damage done during the period of untreated deficiency may not be fully reversible and that other factors play a role.¹⁴

Fluid Retention and Blood Pressure

One of the most immediate effects of taking growth hormone, even at therapeutic doses, is fluid retention. The body holds on to more sodium and water, which increases the volume of fluid in and around cells. A study of GH-deficient adults starting replacement therapy found that body sodium and extracellular water both rose, though blood pressure did not increase acutely. The researchers concluded that this sodium retention is a direct effect of GH on the kidneys rather than a consequence of changes in hormones like aldosterone.¹⁵

However, the mechanism is more complex than a simple kidney effect. Separate research demonstrated that GH activates the renin-angiotensin-aldosterone system (RAAS), a hormonal cascade that regulates blood pressure and fluid balance. When researchers blocked this system using either an ACE inhibitor or an aldosterone blocker, the fluid retention caused by GH was completely prevented.¹⁶ For people taking GH who experience swelling, joint pain, or carpal tunnel symptoms, this finding helps explain why those side effects happen and points toward potential management strategies.

In the short term, the fluid retention from therapeutic-dose GH does not typically translate into hypertension. Over the long term, however, the picture is less clear, particularly in people who are taking doses above what a deficient body actually needs.

The Insulin Resistance Problem

Growth hormone is a counterregulatory hormone, meaning one of its jobs is to oppose insulin’s effects on blood sugar. When you take GH, your cells become less responsive to insulin, and your body compensates by pumping out more of it. Every study that has measured fasting insulin levels during GH therapy has found them elevated.¹⁷ Fasting blood glucose tends to rise modestly, and a smaller number of patients develop impaired glucose tolerance or new-onset diabetes.

This matters for the heart because insulin resistance is itself a cardiovascular risk factor, even at levels that do not cross the threshold for diabetes. The paradox is striking: GH replacement in deficient adults improves body composition (more muscle, less fat) and lowers cholesterol, both of which should protect the heart, while simultaneously making cells less sensitive to insulin, which should raise risk.¹⁸ In clinical practice, the worsening of insulin sensitivity during GH treatment is generally small, and the beneficial effects on cholesterol and body composition may offset it. But for someone who already has borderline blood sugar or metabolic syndrome, the additional insulin resistance from GH therapy could tip the balance toward harm.

Off-Label and Anti-Aging Use

Much of the public concern about growth hormone and the heart stems not from patients with genuine deficiency but from healthy adults who take it hoping to slow aging, build muscle, or lose fat. The marketing for these uses tends to highlight the favorable body-composition effects while downplaying the risks. A review in the gerontology literature found that while GH given to non-elderly deficient adults does improve body composition and reduce cholesterol, it commonly causes carpal tunnel syndrome, joint pain, swelling, glucose intolerance, and a possible increase in cancer risk. In older adults without a diagnosed deficiency, the evidence for meaningful functional benefits or life extension simply was not there.¹⁹

The heart-related concern with off-label use is straightforward: if you already produce normal amounts of growth hormone and you add more from outside, you are mimicking a mild version of acromegaly. The cardiac consequences may not appear as dramatically as in someone with a pituitary tumor, but the same processes, wall thickening, stiffening, and fibrosis, can be set in motion. A preliminary study of GH given to patients with dilated cardiomyopathy (not GH-deficient) found that the improvements in heart size, function, and exercise tolerance were partially reversed after GH was stopped, suggesting the effects were dependent on continued exposure and not a permanent fix.²⁰ More telling: a randomized, placebo-controlled trial of GH in heart failure patients with dilated cardiomyopathy was conducted but failed to establish clear lasting benefits.²¹

For otherwise healthy adults, the risk-benefit calculation is especially unfavorable. You gain modest changes in body composition that could be achieved with exercise and diet, while exposing your heart to fluid retention, insulin resistance, and the early stages of pathological thickening, none of which come with exercise.

Childhood GH Treatment and Long-Term Heart Risk

A large population-based study tracked children who received GH treatment into adulthood and compared their cardiovascular outcomes to matched controls. The results raised eyebrows: treated children had roughly 70% higher overall cardiovascular event rates after adjustment, with the risk climbing higher in those who were treated for longer or received larger cumulative doses. Women appeared to face an even greater relative increase in risk than men, and the association held across different reasons for childhood treatment, including growth hormone deficiency, being born small, and short stature without a clear hormonal cause. The risk of severe cardiovascular events was roughly doubled.²²

This study is important but carries caveats. The children who receive GH treatment are not identical to the general population; they have underlying conditions that may independently raise cardiovascular risk. Observational data like this cannot prove that GH caused the excess events rather than being a marker for an underlying susceptibility. Still, the dose-response pattern, with longer treatment and higher doses linked to more cardiovascular events, is the kind of signal that raises genuine concern and justifies ongoing monitoring of people who received GH in childhood.

Do Men and Women Respond Differently?

There are reasons to think they might. The childhood study above found a larger relative risk increase in women. A study specifically investigating sex differences during adult GH replacement therapy found that men showed greater early improvements in waist circumference, waist-to-hip ratio, total cholesterol, and triglycerides compared to women. However, those between-sex differences faded over longer follow-up, and when the researchers looked at actual cardiovascular and cerebrovascular events during treatment, they found no significant difference between men and women.²³

The picture is unsettled. Metabolic responses to GH therapy may differ between sexes in timing and magnitude, but whether that translates into meaningfully different cardiovascular outcomes is still unclear. For clinicians, the practical takeaway is that women on GH replacement may need slightly different monitoring, especially early in treatment when the metabolic benefits lag behind those seen in men.

Genetics and Individual Susceptibility

Not everyone’s heart responds to growth hormone in the same way, and part of the reason is genetic. The growth hormone receptor comes in different forms. One common variant, called GHRd3, involves a deletion in the gene that encodes the receptor. A study of an Indian cohort with coronary artery disease found that carrying the GHRd3 deletion was associated with significantly lower odds of coronary disease and with higher levels of HDL cholesterol, the so-called “good” cholesterol.²⁴

Meanwhile, a separate study looked at the same receptor variant in relation to hypertension and stroke. It found no overall link between the GHRd3 variant and either condition in the general sample, but among stroke patients, particularly women, there was an association between the variant and hypertension.²⁵ The same study also identified weak links between growth hormone gene promoter variants and blood pressure levels in hypertensive patients.

These genetic findings are still early-stage and population-specific, so they are not ready to guide clinical decisions. But they point toward a future where a person’s genetic profile helps predict how their cardiovascular system will respond to growth hormone, whether their own body makes too much, too little, or they take it as a drug. For now, the practical lesson is that two people taking the same dose of GH may experience different cardiovascular consequences, and individual monitoring matters more than population averages.

A Natural Experiment in Lifelong GH Deficiency

Some of the most intriguing data come from communities with inherited growth hormone receptor deficiency, a condition in which the body cannot respond to GH at all. Earlier studies of one such group found that the rate of cardiovascular-related deaths was comparable between affected individuals and their unaffected relatives, roughly 30% versus 33%.²⁶ These individuals have essentially zero IGF-1 activity throughout life, yet they do not appear to die of heart disease at dramatically higher rates. They do show some protective metabolic features, including enhanced insulin sensitivity, which may offset the cardiac disadvantages of having no GH signaling at all.

This natural experiment complicates the simple narrative that more GH is always better for the heart. It suggests that the human cardiovascular system can adapt to very low GH/IGF-1 activity over a lifetime, and that the metabolic context, particularly insulin sensitivity and body composition, may matter as much as the GH level itself. It also raises the possibility that the cardiovascular harm seen in acquired adult GH deficiency is partly driven by the metabolic disruption that accompanies it, not solely by the loss of GH’s direct effects on the heart.